HIKAL
|
HIKAL Last 5 Year Cashflow Statement History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Profit Before Tax | ₹96 Cr | ₹105 Cr | ₹219 Cr | ₹206 Cr | ₹142 Cr |
Adjustment | ₹175 Cr | ₹163 Cr | ₹126 Cr | ₹127 Cr | ₹136 Cr |
Changes In working Capital | ₹-53 Cr | ₹76 Cr | ₹19 Cr | ₹-58 Cr | ₹46 Cr |
Cash Flow after changes in Working Capital | ₹217 Cr | ₹344 Cr | ₹364 Cr | ₹276 Cr | ₹325 Cr |
Cash Flow from Operating Activities | ₹187 Cr | ₹315 Cr | ₹294 Cr | ₹229 Cr | ₹285 Cr |
Cash Flow from Investing Activities | ₹-174 Cr | ₹-292 Cr | ₹-284 Cr | ₹-156 Cr | ₹-164 Cr |
Cash Flow from Financing Activities | ₹-27 Cr | ₹-7.68 Cr | ₹-5.56 Cr | ₹-97 Cr | ₹-101 Cr |
Net Cash Inflow / Outflow | ₹-14 Cr | ₹15 Cr | ₹3.80 Cr | ₹-24 Cr | ₹20 Cr |
Opening Cash & Cash Equivalents | ₹27 Cr | ₹11 Cr | ₹7.64 Cr | ₹32 Cr | ₹11 Cr |
Cash & Cash Equivalent on Amalgamation / Take over / Merger | - | - | - | - | - |
Cash & Cash Equivalent of Subsidiaries under liquidations | - | - | - | - | - |
Translation adjustment on reserves / op cash balalces frgn subsidiaries | - | - | - | - | - |
Effect of Foreign Exchange Fluctuations | - | - | - | - | - |
Closing Cash & Cash Equivalent | ₹13 Cr | ₹27 Cr | ₹11 Cr | ₹7.64 Cr | ₹32 Cr |
Compare Cashflow Statement of peers of HIKAL
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
HIKAL | ₹4,352.5 Cr | 3.6% | -3.2% | -3.6% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹408,667.0 Cr | 1.8% | 3.4% | 7.3% | Stock Analytics | |
DIVIS LABORATORIES | ₹180,131.0 Cr | -0.7% | 3.8% | 49.3% | Stock Analytics | |
CIPLA | ₹119,745.0 Cr | -0.2% | -1.1% | -2.8% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹118,603.0 Cr | 5.8% | 8.6% | 17.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹105,429.0 Cr | 0.7% | -3.8% | -7.3% | Stock Analytics |
HIKAL Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
HIKAL | 3.6% |
-3.2% |
-3.6% |
SENSEX | -1.1% |
0.8% |
2.2% |
You may also like the below Video Courses